 |
|
|
| |
VTP-300 immunotherapeutic, plus low dose PD-1 inhibitor,
nivolumab, continues to show meaningful, sustained reductions in HBsAg levels
|
| |
| |
EASL 2024 June 5-8 Milan Italy
Dereck Tait1, Louise Bussey1, Radka Kolenovska1, Matt Downs1, Katie Anderson1, Antonella Vardeu1, Man-Fung Yuen2,
Wan-Long Chuang3, Chun-Jen Liu4, Apinya Leerapun5,
Pisit Tangkijvanich6. 1Barinthus Biotherapeutics, Didcot, Oxford, United Kingdom; 2Queen Mary Hospital, Hong Kong, Hong Kong; 3Kaohsiung Medical University ChungHho Memorial Hospital, Kaohsiung City, Taiwan; 4National Taiwan University Hospital, Taipei City, Taiwan; 5Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand; 6King Chulalongkorn Memorial Hospital, Bangkok, Thailand
|
| |
|
|
|
|
|
